Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Alight Solutions Q1 2026 Earnings Call - New CEO Exceeds Guidance Amidst Recurring Revenue Decline and Strategic Leadership Hires
Alight Solutions delivered a stronger-than-expected first quarter of 2026, with revenue of $534 million beating the high-single-digit decline guidance. The outperformance was driven by a 29% surge in ...
- Revenue of $534 million exceeded guidance, driven by a 29% year-over-year increase in project revenue to $36 million and earlier-than-expected partner revenue recognition.
- Recurring revenue declined 4% year-over-year to $498 million, partially offset by the project revenue surge, resulting in a consolidated 3% revenue decrease.
- Adjusted EBITDA of $104 million fell 12% year-over-year but beat expectations, supported by project revenue flow-through and lower-than-anticipated employee healthcare expenses.
- +9 more takeaways
Cumberland Pharmaceuticals Q1 2026 Earnings Call - Apotex Deal Unlocks $109M Cash, Pivots to Pipeline
Cumberland Pharmaceuticals is selling its entire commercial portfolio to Apotex for $109 million in cash, marking a decisive pivot from a branded drug marketer to a pure-play development-stage biotech...
- Cumberland Pharmaceuticals signed a transformative agreement to sell its entire portfolio of marketed products to Apotex for $100 million in cash, subject to shareholder approval.
- The transaction includes an additional $9 million for inventory, transitional support services, and a milestone payment tied to future product sales.
- Cumberland will no longer target double-digit revenue growth, as Apotex will assume all sales, marketing, medical, manufacturing, and FDA fee responsibilities post-close.
- +7 more takeaways
BigBear.ai Q1 2026 Earnings Call - Backlog Surges 14% as GenAI Shift Boosts Margins
BigBear.ai reported Q1 2026 revenue of $34.4 million, flat year-over-year, but the real story is the structural pivot underway. Gross margins expanded nearly 1,300 basis points to 34%, driven by a del...
- Revenue of $34.4 million remained flat year-over-year, but gross margins expanded nearly 1,300 basis points to 34%, reflecting a successful shift toward higher-margin generative AI platforms post-Ack Sage acquisition.
- Backlog surged 14% to $281.9 million, driven by a $53 million classified sole-source intelligence contract and new wins in shipbuilding simulation and airport travel screening.
- The company is restructuring its go-to-market approach by aligning dedicated sales, technology, and delivery teams directly around national security and trade operators to accelerate execution.
- +7 more takeaways
Entravision Communications Q1 2026 Earnings Call - ATS Drives 114% Revenue Surge as Media Segment Invests for Turnaround
Entravision Communications reported a 114% year-over-year revenue increase to $197 million in Q1 2026, driven almost entirely by explosive growth in its Advertising Technology and Services (ATS) segme...
- Consolidated revenue surged 114% to $197 million in Q1 2026, reversing a prior-year operating loss into a $20.7 million operating income.
- ATS segment revenue exploded 204% to $155 million, with operating profit jumping 427% to $34.3 million, highlighting the segment's scalability.
- Media segment revenue grew just 4% to $42.4 million, but posted a widened operating loss of $5.2 million versus $2.6 million loss in Q1 2025 due to higher cost of revenue and strategic investments.
- +7 more takeaways
Skyworks Solutions Q2 FY2026 Earnings Call - Android Design Win and Qorvo Merger Progress Drive Outlook
Skyworks Solutions delivered a strong Q2 FY2026, posting revenue of $944M and EPS of $1.15, both beating guidance. The results were fueled by healthy mobile sell-through and robust broad market growth...
- Skyworks Solutions reported Q2 FY2026 revenue of $944 million, exceeding the high end of its guidance range by approximately $20 million.
- Diluted earnings per share came in at $1.15, beating the high end of guidance by $0.05 and the midpoint by $0.11.
- The company secured a multi-generational design win with a leading Android OEM, expected to generate over $1 billion in revenue through 2030.
- +10 more takeaways
Trevi Therapeutics Q1 2026 Earnings Call - Securing 2030 Runway and Launching Pivotal IPF Trials
Trevi Therapeutics has secured its financial future through a strategic capital raise, extending its cash runway to 2030 while positioning itself to fund pivotal Phase III trials for its lead chronic ...
- Trevi ended Q1 2026 with $172 million in cash and marketable securities, excluding $162 million in net proceeds from an underwritten common stock offering completed in April 2026.
- The recent capital raise extends Trevi's cash runway through 2030, funding development through potential FDA approval for IPF-related chronic cough and pre-commercial activities.
- Phase III protocols for IPF-related chronic cough are finalized, with the first pivotal study expected to initiate this quarter and the second in the second half of 2026.
- +9 more takeaways
Tempus AI Q1 2026 Earnings Call - Data Licensing Revenue Surges 40% as Pharma Shifts to AI Model Partnerships
Tempus AI delivered a quarter of broad-based strength, with total revenue climbing 36% to $348.1 million and data and applications revenue jumping 40.5% to $87 million. The diagnostic business grew 35...
- Total revenue reached $348.1 million, up 36% year-over-year, driven by strength across both diagnostic and data segments.
- Diagnostic revenue grew 35% to $261.1 million, with solid tumor and liquid biopsy volumes up 28% year-over-year.
- Data and applications revenue surged 40.5% to $87 million, with insights and modeling revenue growing over 44%.
- +9 more takeaways
Cytokinetics Q1 2026 Earnings Call - MYQORZO Launch Exceeds Expectations, ACACIA-HCM Delivers Positive Results
Cytokinetics entered commercial stage with the U.S. launch of MYQORZO, reporting $4.8 million in net product revenue within nine weeks of availability. The launch exceeded internal expectations, drive...
- MYQORZO U.S. Launch Exceeds Early Metrics: The company reported $4.8 million in net product revenue during the quarter, reflecting approximately nine weeks of sales. Over 70% of dispensed patients converted to paid prescriptions in under two weeks, and more than 425 HCPs had prescribed the drug by April.
- ACACIA-HCM Phase III Trial Meets Primary Endpoints: Aficamten demonstrated statistically significant improvements in both the KCCQ clinical summary score (3-point difference vs. placebo) and peak VO2 (0.67 ml/kg/min difference) in patients with non-obstructive HCM. No new safety signals were observed.
- Regulatory Momentum for Aficamten Expansion: Cytokinetics plans to submit a supplemental NDA to the FDA for aficamten in non-obstructive HCM following the ACACIA-HCM results. The sNDA for the MAPLE-HCM trial was accepted for filing, with a PDUFA date set for November 14, 2026.
- +7 more takeaways
América Móvil Q1 2026 Earnings Call - Operating Leverage Drives Record Margins Amid Strategic M&A Readiness
América Móvil delivered a resilient first quarter of 2026, with EBITDA expanding 8% at constant exchange rates and service revenue growth accelerating across its core markets. The company’s discipline...
- EBITDA grew 8% at constant exchange rates, outpacing service revenue growth of 4.6%, driven by structural operating leverage and disciplined cost management.
- Consolidated EBITDA margin reached 40%, a multi-year high, reflecting successful network upgrades and digitalization of internal processes.
- Service revenue growth accelerated in Mexico and Colombia, with postpaid revenue up 7.3% and prepaid recovering as regional economic conditions improve.
- +7 more takeaways
WEC Energy Group Q1 2026 Earnings Call - Data Center Tariff Approval Fuels Growth and Execution Confidence
WEC Energy Group reported a solid start to 2026 with first-quarter earnings of $2.45 per share, driven by rate-based growth, favorable operational timing, and continued capital execution. The company ...
- Q1 2026 earnings reached $2.45 per share, up $0.18 year-over-year, reflecting strong operational execution and rate-based growth.
- The Wisconsin Public Service Commission verbally approved the Very Large Customer (VLC) tariff, ensuring hyperscalers like Microsoft and Vantage Data Centers pay their full share.
- Management reaffirmed 2026 earnings guidance of $5.51 to $5.61 per share, assuming normal weather for the remainder of the year.
- +7 more takeaways